Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global vaccine market is expected to exhibit a CAGR of 10.33% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

From a public health perspective, vaccines represent among the most important inventions in human history. A vaccine refers to a biological component that stimulates the production of antibodies against several pathogens present in the body. It is generally produced by using disease-causing agents and chemical drugs that act as antigens in disease prevention. Vaccines are primarily available in the form of conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. They help in preventing various life-threatening diseases, including measles, polio, diphtheria, meningitis, influenza, tetanus, rotavirus, hepatitis, etc. As a result, vaccines are widely adopted for several immunization procedures, across hospitals, clinics, and vaccination centers, and for research purposes in academic and clinical laboratories.

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

The high prevalence of several infectious diseases is primarily driving the demand for vaccines. The growing consumer awareness towards effective immunization for eradicating various infections is further catalyzing the market growth. Moreover, the introduction of several vaccination programs by governments across various endemic regions is also propelling the demand for vaccines. Additionally, the market is also driven by the growing number of child deaths due to various infectious diseases, such as hepatitis, polio, measles, rubella, etc., particularly across the under-developed countries. The increasing involvement of several global organizations, such as the WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation, etc. for developing adequate vaccination facilities in the endemic regions, is further catalyzing the product demand. Several pharmaceutical companies are focusing on the development of new and improved vaccines by accelerating the clinical trials of various pipeline drugs. Extensive R&D activities pertaining to the immunization of several fatal diseases, such as AIDS, Ebola, Hepatitis C, paratyphoid fever, etc., are also expected to fuel the market growth. The outbreak of the COVID-19 pandemic, leading to around half a million global deaths (as of June 2020), is currently creating opportunities for a novel vaccine against COVID-19.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Breakup by Technology:

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Others
     

Breakup by Patient Type:

  • Paediatric
  • Adult
     

Breakup by Indication:

  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis (DPT)
    • Tuberculosis
    • Haemophilus Influenzae (Hib)
    • Typhoid
    • Others
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus (HPV)
    • Measles/Mumps/Rubella (MMR)
    • Rotavirus
    • Herpes Zoster
    • Varicella
    • Japanese Encephalitis
    • Rubella
    • Polio
    • Rabies
    • Dengue
    • Others
       

Breakup by Route of Administration:

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others
     

Breakup by Product Type:

  • Multivalent Vaccine
  • Monovalent Vaccine
     

Breakup by Treatment Type:

  • Preventive Vaccine
  • Therapeutic Vaccine
     

Breakup by End User:

  • Hospitals
  • Clinics
  • Vaccination Centres
  • Academic and Research Institutes
  • Others
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others
     

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • Turkey
    • GCC Countries
    • Israel
    • Others
       

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bharat Biotech International, Bavarian Nordic A/S, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson & Johnson, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Mexico, Turkey, GCC Countries, Israel
Companies Covered Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bharat Biotech International, Bavarian Nordic A/S, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson & Johnson, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

    4.1    Overview
    4.2    Key Industry Trends
       4.2.1 Regulatory Landscape
           4.2.1.1 United States
           4.2.1.2 Canada
           4.2.1.3 European Union
           4.2.1.4 China
           4.2.1.5 India
           4.2.1.6 Japan
           4.2.1.7 South Korea
           4.2.1.8 Australia
           4.2.1.9 Russia
           4.2.1.10 Brazil
           4.2.1.11 Mexico
           4.2.1.12 Turkey
           4.2.1.13 GCC Countries
           4.2.1.14 Israel
        4.2.2 Product Pipeline for New Vaccines 
           4.2.2.1 Product Pipeline for HIV 
           4.2.2.2 Product Pipeline for Zika Virus
           4.2.2.3 Product Pipeline for Ebola Virus
           4.2.2.4 Product Pipeline for COVID-19
5   Global Vaccine Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Technology
    6.1    Conjugate Vaccines
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Inactivated and Subunit Vaccines
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Live Attenuated Vaccines
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Recombinant Vaccines
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Toxoid Vaccines
        6.5.1 Market Trends
        6.5.2 Market Forecast
    6.6    Others
        6.6.1 Market Trends
        6.6.2 Market Forecast
7   Market Breakup by Patient Type
    7.1    Paediatric
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Adult
        7.2.1 Market Trends
        7.2.2 Market Forecast
8   Market Breakup by Indication
    8.1    Bacterial Diseases
        8.1.1 Market Trends
        8.1.2 Major Types
           8.1.2.1   Meningococcal Disease
              8.1.2.1.1 Market Trends
              8.1.2.1.2 Market Forecast
           8.1.2.2   Pneumococcal Disease
             8.1.2.2.1 Market Trends
             8.1.2.2.2 Market Forecast
           8.1.2.3   Diphtheria/Tetanus/Pertussis (DPT)
               8.1.2.3.1 Market Trends
               8.1.2.3.2 Market Forecast
           8.1.2.4   Tuberculosis
               8.1.2.4.1 Market Trends
               8.1.2.4.2 Market Forecast
           8.1.2.5   Haemophilus Influenzae (Hib)
               8.1.2.5.1 Market Trends
               8.1.2.5.2 Market Forecast
           8.1.2.6   Typhoid
               8.1.2.6.1 Market Trends
               8.1.2.6.2 Market Forecast
           8.1.2.7   Others
               8.1.2.7.1 Market Trends
               8.1.2.7.2 Market Forecast
        8.1.3 Market Forecast                   
    8.2    Viral Diseases
        8.2.1 Market Trends
        8.2.2 Major Types
           8.2.2.1   Hepatitis
               8.2.2.1.1 Market Trends
               8.2.2.1.2 Market Forecast
           8.2.2.2   Influenza               
               8.2.2.2.1 Market Trends
               8.2.2.2.2 Market Forecast
           8.2.2.3   Human Papillomavirus (HPV)
               8.2.2.3.1 Market Trends
               8.2.2.3.2 Market Forecast
           8.2.2.4   Measles/Mumps/Rubella (MMR)
               8.2.2.4.1 Market Trends
               8.2.2.4.2 Market Forecast
           8.2.2.5   Rotavirus
               8.2.2.5.1 Market Trends
               8.2.2.5.2 Market Forecast
           8.2.2.6   Herpes Zoster
               8.2.2.6.1 Market Trends
               8.2.2.6.2 Market Forecast
           8.2.2.7   Varicella
               8.2.2.7.1 Market Trends
               8.2.2.7.2 Market Forecast
           8.2.2.8   Japanese Encephalitis
               8.2.2.8.1 Market Trends
               8.2.2.8.2 Market Forecast
           8.2.2.9   Rubella
               8.2.2.9.1 Market Trends
               8.2.2.9.2 Market Forecast
           8.2.2.10   Polio
               8.2.2.10.1 Market Trends
               8.2.2.10.2 Market Forecast
           8.2.2.11   Rabies
               8.2.2.11.1 Market Trends
               8.2.2.11.2 Market Forecast
           8.2.2.12   Dengue
               8.2.2.12.1 Market Trends
               8.2.2.12.2 Market Forecast
           8.2.2.13   Others
               8.2.2.13.1 Market Trends
               8.2.2.13.2 Market Forecast
        8.2.3 Market Forecast
9   Market Breakup by Route of Administration
    9.1    Intramuscular and Subcutaneous Administration
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Oral Administration
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Others
        9.3.1 Market Trends
        9.3.2 Market Forecast
10  Market Breakup by Product Type
    10.1    Multivalent Vaccine
        10.1.1 Market Trends
        10.1.2 Market Forecast
    10.2    Monovalent Vaccine
        10.2.1 Market Trends
        10.2.2 Market Forecast
11  Market Breakup by Treatment Type
    11.1    Preventive Vaccine
        11.1.1 Market Trends
        11.1.2 Market Forecast
    11.2    Therapeutic Vaccine
        11.2.1 Market Trends
        11.2.2 Market Forecast
12  Market Breakup by End User
    12.1    Hospitals
        12.1.1 Market Trends
        12.1.2 Market Forecast
    12.2    Clinics
        12.2.1 Market Trends
        12.2.2 Market Forecast
    12.3    Vaccination Centres
        12.3.1 Market Trends
        12.3.2 Market Forecast
    12.4    Academic and Research Institutes
        12.4.1 Market Trends
        12.4.2 Market Forecast
    12.5    Others
        12.5.1 Market Trends
        12.5.2 Market Forecast
13  Market Breakup by Distribution Channel
    13.1    Hospital Pharmacies
        13.1.1 Market Trends
        13.1.2 Market Forecast
    13.2    Retail Pharmacies
        13.2.1 Market Trends
        13.2.2 Market Forecast
    13.3    Institutional Sales
        13.3.1 Market Trends
        13.3.2 Market Forecast
    13.4    Others
        13.4.1 Market Trends
        13.4.2 Market Forecast
14  Market Breakup by Region
    14.1    North America
        14.1.1 United States
           14.1.1.1 Market Trends
           14.1.1.2 Market Forecast
        14.1.2 Canada
           14.1.2.1 Market Trends
           14.1.2.2 Market Forecast
    14.2    Asia Pacific
        14.2.1 China
           14.2.1.1 Market Trends
           14.2.1.2 Market Forecast
        14.2.2 Japan
           14.2.2.1 Market Trends
           14.2.2.2 Market Forecast
        14.2.3 India
           14.2.3.1 Market Trends
           14.2.3.2 Market Forecast
        14.2.4 South Korea
           14.2.4.1 Market Trends
           14.2.4.2 Market Forecast
        14.2.5 Australia
           14.2.5.1 Market Trends
           14.2.5.2 Market Forecast
        14.2.6 Others
           14.2.6.1 Market Trends
           14.2.6.2 Market Forecast
    14.3    Europe
        14.3.1 Germany
           14.3.1.1 Market Trends
           14.3.1.2 Market Forecast
        14.3.2 France
           14.3.2.1 Market Trends
           14.3.2.2 Market Forecast
        14.3.3 United Kingdom
           14.3.3.1 Market Trends
           14.3.3.2 Market Forecast
        14.3.4 Italy
           14.3.4.1 Market Trends
           14.3.4.2 Market Forecast
        14.3.5 Spain
           14.3.5.1 Market Trends
           14.3.5.2 Market Forecast
        14.3.6 Russia
           14.3.6.1 Market Trends
           14.3.6.2 Market Forecast
        14.3.7 Others
           14.3.7.1 Market Trends
           14.3.7.2 Market Forecast
    14.4    Latin America
        14.4.1 Brazil
           14.4.1.1 Market Trends
           14.4.1.2 Market Forecast
        14.4.2 Mexico
           14.4.2.1 Market Trends
           14.4.2.2 Market Forecast
        14.4.3 Others
           14.4.3.1 Market Trends
           14.4.3.2 Market Forecast
    14.5    Middle East and Africa
        14.5.1 Turkey
           14.5.1.1 Market Trends
           14.5.1.2 Market Forecast
        14.5.2 GCC Countries
           14.5.2.1 Market Trends
           14.5.2.2 Market Forecast
        14.5.3 Israel
           14.5.3.1 Market Trends
           14.5.3.2 Market Forecast
        14.5.4 Others
           14.5.4.1 Market Trends
           14.5.4.2 Market Forecast
15  SWOT Analysis
    15.1    Overview
    15.2    Strengths
    15.3    Weaknesses
    15.4    Opportunities
    15.5    Threats
16  Value Chain Analysis
    16.1    Exploratory Stage
    16.2    Preclinical and Clinical Development
    16.3    Regulatory Approval
    16.4    Manufacturing
    16.5    Marketing and Distribution
17  Porters Five Forces Analysis
    17.1    Overview
    17.2    Bargaining Power of Buyers
    17.3    Bargaining Power of Suppliers
    17.4    Degree of Competition
    17.5    Threat of New Entrants
    17.6    Threat of Substitutes
18  Price Analysis
19  Major Drivers and Challenges
20  Competitive Landscape

    20.1    Market Structure
    20.2    Key Players
    20.3    Profiles of Key Players
        20.3.1    Abbott Laboratories
           20.3.1.1 Company Overview
           20.3.1.2 Product Portfolio 
           20.3.1.3 Financials
           20.3.1.4 SWOT Analysis
        20.3.2    Astellas Pharma Inc.
           20.3.2.1 Company Overview
           20.3.2.2 Product Portfolio 
           20.3.2.3 Financials
           20.3.2.4 SWOT Analysis
        20.3.3    AstraZeneca Plc
           20.3.3.1 Company Overview
           20.3.3.2 Product Portfolio 
           20.3.3.3 Financials
           20.3.3.4 SWOT Analysis
        20.3.4   Bharat Biotech International
           20.3.4.1 Company Overview
           20.3.4.2 Product Portfolio 
        20.3.5    Bavarian Nordic A/S
           20.3.5.1 Company Overview
           20.3.5.2 Product Portfolio 
           20.3.5.3 Financials
        20.3.6    CSL Limited
           20.3.6.1 Company Overview
           20.3.6.2 Product Portfolio 
           20.3.6.3 Financials
           20.3.6.4 SWOT Analysis
        20.3.7    Daiichi Sankyo Company Limited
           20.3.7.1 Company Overview
           20.3.7.2 Product Portfolio 
        20.3.8    Emergent BioSolutions Inc.
           20.3.8.1 Company Overview
           20.3.8.2 Product Portfolio 
           20.3.8.3 Financials
           20.3.8.4 SWOT Analysis
        20.3.9    GlaxoSmithKline Plc
           20.3.9.1 Company Overview
           20.3.9.2 Product Portfolio 
           20.3.9.3 Financials
           20.3.9.4 SWOT Analysis
        20.3.10    Inovio Pharmaceuticals Inc.
           20.3.10.1 Company Overview
           20.3.10.2 Product Portfolio 
           20.3.10.3 Financials
           20.3.10.4 SWOT Analysis
        20.3.11    Johnson & Johnson
           20.3.11.1 Company Overview
           20.3.11.2 Product Portfolio 
           20.3.11.3 Financials
           20.3.11.4 SWOT Analysis
        20.3.12    Merck & Co. Inc.
           20.3.12.1 Company Overview
           20.3.12.2 Product Portfolio 
           20.3.12.3 Financials
           20.3.12.4 SWOT Analysis
        20.3.13    Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
           20.3.13.1 Company Overview
           20.3.13.2 Product Portfolio 
           20.3.13.3 Financials
           20.3.13.4 SWOT Analysis
        20.3.14    Novavax Inc.
           20.3.14.1 Company Overview
           20.3.14.2 Product Portfolio 
           20.3.14.3 Financials
           20.3.14.4 SWOT Analysis
        20.3.15    Panacea Biotec Ltd.
           20.3.15.1 Company Overview
           20.3.15.2 Product Portfolio 
        20.3.16    Pfizer Inc.
           20.3.16.1 Company Overview
           20.3.16.2 Product Portfolio 
           20.3.16.3 Financials
           20.3.16.4 SWOT Analysis
        20.3.17    Sanofi Pasteur SA (Sanofi SA)
           20.3.17.1 Company Overview
           20.3.17.2 Product Portfolio 
           20.3.17.3 Financials
           20.3.17.4 SWOT Analysis
        20.3.18    Serum Institute of India Pvt. Ltd.
           20.3.18.1 Company Overview
           20.3.18.2 Product Portfolio 
        20.3.19    Takeda Pharmaceutical Company Limited
           20.3.19.1 Company Overview
           20.3.19.2 Product Portfolio 
           20.3.19.3 Financials
           20.3.19.4 SWOT Analysis

List of Figures

Figure 1: Global: Vaccine Market: Major Drivers and Challenges
Figure 2: Global: Vaccine Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Vaccine Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Vaccine Market: Breakup by Technology (in %), 2021
Figure 5: Global: Vaccine Market: Breakup by Patient Type (in %), 2021
Figure 6: Global: Vaccine Market: Breakup by Indication (in %), 2021
Figure 7: Global: Vaccine Market: Breakup by Route of Administration (in %), 2021
Figure 8: Global: Vaccine Market: Breakup by Product Type (in %), 2021
Figure 9: Global: Vaccine Market: Breakup by Treatment Type (in %), 2021
Figure 10: Global: Vaccine Market: Breakup by End User (in %), 2021
Figure 11: Global: Vaccine Market: Breakup by Distribution Channel (in %), 2021
Figure 12: Global: Vaccine Market: Breakup by Region (in %), 2021
Figure 13: Global: Vaccine (Conjugate Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Vaccine (Conjugate Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Vaccine (Inactivated and Subunit Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Vaccine (Inactivated and Subunit Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Vaccine (Live Attenuated Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Vaccine (Live Attenuated Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Vaccine (Recombinant Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Vaccine (Recombinant Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Vaccine (Toxoid Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Vaccine (Toxoid Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Vaccine (Other Technologies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Vaccine (Other Technologies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Vaccine (Paediatric) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Vaccine (Paediatric) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Vaccine (Adult) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Vaccine (Bacterial Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Vaccine (Bacterial Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Vaccine (Meningococcal Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Vaccine (Meningococcal Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Vaccine (Pneumococcal Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Vaccine (Pneumococcal Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Vaccine (Tuberculosis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Vaccine (Tuberculosis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Vaccine (Haemophilus Influenzae-Hib) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Vaccine (Haemophilus Influenzae-Hib) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Global: Vaccine (Typhoid) Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Global: Vaccine (Typhoid) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Global: Vaccine (Other Bacterial Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Global: Vaccine (Other Bacterial Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Global: Vaccine (Viral Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Global: Vaccine (Viral Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Global: Vaccine (Hepatitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Global: Vaccine (Hepatitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Global: Vaccine (Influenza) Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Global: Vaccine (Influenza) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Global: Vaccine (Human Papillomavirus-HPV) Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Global: Vaccine (Human Papillomavirus-HPV) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Global: Vaccine (Rotavirus) Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Global: Vaccine (Rotavirus) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Global: Vaccine (Herpes Zoster) Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Global: Vaccine (Herpes Zoster) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Global: Vaccine (Varicella) Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Global: Vaccine (Varicella) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Global: Vaccine (Japanese Encephalitis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Global: Vaccine (Japanese Encephalitis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Global: Vaccine (Rubella) Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Global: Vaccine (Rubella) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Global: Vaccine (Polio) Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Global: Vaccine (Polio) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Global: Vaccine (Rabies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Global: Vaccine (Rabies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Global: Vaccine (Dengue) Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Global: Vaccine (Dengue) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Global: Vaccine (Other Viral Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Global: Vaccine (Other Viral Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Global: Vaccine (Oral Administration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Global: Vaccine (Oral Administration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Global: Vaccine (Other Routes of Administration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Global: Vaccine (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Global: Vaccine (Multivalent Vaccine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Global: Vaccine (Multivalent Vaccine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Global: Vaccine (Monovalent Vaccine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Global: Vaccine (Monovalent Vaccine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Global: Vaccine (Preventive Vaccine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Global: Vaccine (Preventive Vaccine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Global: Vaccine (Therapeutic Vaccine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Global: Vaccine (Therapeutic Vaccine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Global: Vaccine (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Global: Vaccine (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Global: Vaccine (Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 90: Global: Vaccine (Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 91: Global: Vaccine (Vaccination Centres) Market: Sales Value (in Million US$), 2016 & 2021
Figure 92: Global: Vaccine (Vaccination Centres) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 93: Global: Vaccine (Academic and Research Institutes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 94: Global: Vaccine (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 95: Global: Vaccine (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 96: Global: Vaccine (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 97: Global: Vaccine (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 98: Global: Vaccine (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 99: Global: Vaccine (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 100: Global: Vaccine (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 101: Global: Vaccine (Institutional Sales) Market: Sales Value (in Million US$), 2016 & 2021
Figure 102: Global: Vaccine (Institutional Sales) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 103: Global: Vaccine (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
Figure 104: Global: Vaccine (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 105: North America: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 106: North America: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 107: United States: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 108: United States: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 109: Canada: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 110: Canada: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 111: Asia Pacific: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 112: Asia Pacific: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 113: China: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 114: China: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 115: Japan: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 116: Japan: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 117: India: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 118: India: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 119: South Korea: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 120: South Korea: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 121: Australia: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 122: Australia: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 123: Others: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 124: Others: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 125: Europe: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 126: Europe: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 127: Germany: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 128: Germany: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 129: France: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 130: France: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 131: United Kingdom: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 132: United Kingdom: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 133: Italy: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 134: Italy: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 135: Spain: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 136: Spain: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 137: Russia: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 138: Russia: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 139: Others: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 140: Others: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 141: Latin America: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 142: Latin America: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 143: Brazil: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 144: Brazil: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 145: Mexico: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 146: Mexico: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 147: Others: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 148: Others: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 149: Middle East and Africa: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 150: Middle East and Africa: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 151: Turkey: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 152: Turkey: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 153: GCC Countries: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 154: GCC Countries: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 155: Israel: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 156: Israel: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 157: Others: Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 158: Others: Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 159: Global: Vaccine Industry: SWOT Analysis
Figure 160: Global: Vaccine Industry: Value Chain Analysis
Figure 161: Global: Vaccine Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Vaccine Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Vaccine Market Forecast: Breakup by Technology (in Million US$), 2022-2027
Table 3: Global: Vaccine Market Forecast: Breakup by Patient Type (in Million US$), 2022-2027
Table 4: Global: Vaccine Market Forecast: Breakup by Indication (in Million US$), 2022-2027
Table 5: Global: Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 6: Global: Vaccine Market Forecast: Breakup by Product Type (in Million US$), 2022-2027
Table 7: Global: Vaccine Market Forecast: Breakup by Treatment Type (in Million US$), 2022-2027
Table 8: Global: Vaccine Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 9: Global: Vaccine Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 10: Global: Vaccine Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 11: Global: Vaccine Market: Competitive Structure
Table 12: Global: Vaccine Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

According to the estimates by IMARC Group, the global vaccine market is expected to grow at a CAGR of 10.33% during 2022-2027.

The rising prevalence of infectious diseases and the growing awareness about effective immunization are among the significant factors impelling the global vaccine market growth.

The increasing focus on the development of new and improved vaccines, along with the introduction and continual launch of various vaccination programs by governments of numerous countries, is bolstering the market growth.

Due to the rapid spread of the coronavirus disease (COVID-19) and the increasing death rate, there is an urgent need to develop novel vaccines to provide effective treatment to patients. Consequently, several organizations are engaging in research and development (R&D) activities, which, in turn, is positively influencing the market growth.

Based on the technology, the market has been classified into conjugate, inactivated and subunit, live attenuated, recombinant, toxoid, and other vaccines.

On the basis of the patient type, the market has been bifurcated into paediatric and adult.

The market has been analyzed on the basis of the indication into bacterial diseases [meningococcal, pneumococcal, diphtheria/tetanus/pertussis (DPT), tuberculosis, Haemophilus influenzae (Hib), typhoid and others] and viral diseases [Hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue and others].

Based on the route of administration, the market has been categorized into intramuscular and subcutaneous administration, oral administration and others.

On the basis of the product type, the market has been divided into multivalent and monovalent vaccines.

The market has been analyzed on the basis of the treatment type into preventive and therapeutic vaccines.

Based on the end user, the market has been classified into hospitals, clinics, vaccination centres, academic and research institutes, and others.

On the basis of the distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, institutional sales and others.

Region-wise, the market has been classified into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia and others); Europe (the United Kingdom, Germany, France, Italy, Spain, Russia and others); Latin America (Brazil, Mexico and others); and the Middle East and Africa (Turkey, GCC Countries, Israel and others).

Leading industry players are Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bharat Biotech International Ltd., Bavarian Nordic A/S, CSL Ltd., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links